Abyntek Biopharma

Pre-clinical

Derio, SpainFounded 2008abyntek.com

Abyntek Biopharma operates as a key supplier in the life sciences research tools market, focusing on the production of antibodies, proteins, and diagnostic kits. While not a traditional drug development biotech, it plays a crucial supporting role in biomedical research by providing essential reagents. The company's strategic direction involves expanding its product portfolio and potentially moving into more advanced diagnostic or therapeutic areas. Its position in the Spanish and European biotech supply chain is well-established.

Founded

2008

Focus

Antibodies

AI Company Overview

Technology Platform

Platform for custom antibody development, recombinant protein production, and immunoassay kit development, leveraging hybridoma technology and protein expression systems.

Funding History

Total raised: $15M

Series A$15MUndisclosedMar 15, 2022

Opportunities

Growth opportunities include expanding its catalog of proprietary reagents, deepening partnerships with diagnostic developers for component supply, and leveraging the growing European biotech R&D sector.

Moving into validated diagnostic antibodies or kits represents a potential vertical expansion.

Risk Factors

Key risks include intense competition from global reagent giants, reliance on the cyclical nature of research funding, and the potential for technological shifts away from antibody-based research methods.

The custom service model may also limit scalability.

Competitive Landscape

Competes against large multinationals like Abcam (Danaher) and Thermo Fisher, as well as numerous niche providers. Differentiation is achieved through specialized custom services, agility, deep expertise in specific targets, and strong regional customer relationships in Spain and Europe.